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Background: Treatment with imatinib mesylate (IM) (a tyrosine kinase inhibitor) is the first line of standard care for
patients newly diagnosed with CML. Despite the success of IM and other tyrosine kinase inhibitors (TKIs), chronic
myeloid leukemia (CML) remains largely incurable, and a number of CML patients die due to Abl mutation-related
drug resistance and blast crisis. 3, 5-Dihydroxy-6, 7, 3′4′-tetramethoxyflavone (DHTMF) is a polymethoxyflavone
isolated from Laggera pterodonta which is a herbal medicine used to treat cancer in the Chinese folk. In the previous
study, we found DHTMF demonstrated good antiproliferative activities against a number of cancer cell lines and
induced the apoptosis of CNE cells in vitro in a time- and dose-dependent manner while exhibiting low cytotoxicity in
the two normal cell lines Vero and EVC304. The aim of the present study was to evaluate the proliferation inhibition
and apoptosis induced by DHTMF alone and in combination with IM in the IM-resistant CML cell line K562R.
Methods: Cell proliferation was assayed with the cell counting kit-8 (CCK8) method. The apoptosis percentage was
determined by flow cytometry (FCM). Mitochondrial transmembrane potential was detected using FCM and confocal
laser-scanning microscopy. The level of proteins involved in apoptosis was detected by Western blotting.
Results: DHTMF suppressed K562R cell viability in both time- and dose-dependent manners. DHTMF combined with
IM enhanced the inhibitory effects and apoptosis in K562R cells as compared with DHTMF alone. DHTMF alone and in
combination with IM significantly decreased the mitochondrial membrane potential and increased the levels of cleaved
caspase-9, caspase-7, caspase-3, and PARP in K562R cells.
Conclusions: We demonstrated that DHTMF could inhibit IM-resistant K562R cell proliferation and induces apoptosis
via the intrinsic mitochondrial apoptotic pathway. These results suggest that DHTMF may be a potential therapeutic
drug with lower side effects against IM resistance in CML cells.
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Chronic myeloid leukemia (CML) is a hematopoietic
stem cell disorder that occurs due to t (9; 22) (q34; q11)
translocations. CML represents approximately 20% of all
adult leukemia cases [1]. The aberrant Philadelphia chro-
mosome has been reported to be the main cause of CML
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unless otherwise stated.The chimeric gene Bcr-Abl encodes a protein with consti-
tutive tyrosine-kinase (TK) activity [2]. CML prognoses
have markedly improved after the introduction of Abl
tyrosine kinase inhibitors (TKIs). Since approved as front-
line CML management in 2001, imatinib mesylate (IM)
has been proven to be effective in achieving high remis-
sion rates and improving prognosis. However, up to 33%
of patients did not achieve an optimal response [3], be-
cause residual CML cells were generally present in the
bone marrow microenvironment and then refractory
to IM [4]. Unfortunately, most CML patients who were
treated with IM undergone relapse once the drug was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The inhibitory effect of IM in K562 and K562R cells
at 24 h.
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and blast crisis resulted in numerous CML patients death
[5]. Next-generation TKIs, such as dasatinib and nilotinib,
as well as other kinase inhibitors including Janus kinase 2
inhibitor and Bruton's tyrosine kinase (BTK) inhibitor,
have been used to overcome IM-resistant cases [6,7]. Des-
pite the increasing success of new TKIs, CML remains
largely incurable, and the development of inducible drug
resistance is a paramount problem in which patients failed
respond to the drugs. How to treat the patients who were
resistant to Bcr-Abl tyrosine kinase inhibitors is an im-
portant and urgent issue for clinical hematology. Thus,
more efforts have been directly focused on developing
new drugs to control CML with IM resistance.
Chinese herbal medicines traditionally used to treat
cancer are an important source of potential anti-cancer
agents [8-11]. Laggera pterodonta is an herbal medicine
which is used for a long time in Chinese folk for the treat-
ment of various inflammations as well as cancers [12].
Naturally occurring flavonoids have been proved to pos-
sess a wide range of biological activities including antitu-
mor activity [13]. Studies have revealed that quite a few
flavonoids could reverse drug resistance through different
apoptosis pathways [14-16]. In our previous study, a poly-
methoxyflavone, 3,5-dihydroxy-6,7,3′4′-tetramethoxyfla-
vone (DHTMF), isolated from Laggera pterodonta was
found to possess good anti-cancer activity [17]. Recently,
polymethoxyflavones are gaining increasing attention due
to their promising anticancer potential. In this study, we
investigated the proliferation inhibition and apoptosis
induced by DHTMF alone and in combination with IM in
the IM-resistant CML cell line K562R.
Results
Effect of DHTMF on cell proliferation
We first verified that the K562R cells we used are IM-
resistant CML cells. After K562 and K562R cells were
treated with different concentrations of IM for 24 h,
their cell viability was determined by the CCK8 assay.
The data indicated that IM preferentially inhibits the
proliferation of IM-sensitive K562 cells. After the K562
and K562R cells were treated with 1 μmol/L IM for 24 h,
the inhibitory ratio for the K562 cells was 69.75, while that
for K562R was only 13.99 (Figure 1). We calculated the
IC50 (50% inhibition concentration) for the K562 cells to
be 0.43 μmol/L, and the IC50 for the K562R cells to be
6.23 μmol/L, which indicated that K562 cells have a mark-
edly lower IC50 compared with K562R cells. The IM
resistance fold-change of the K562R cells was 14.49.
To determine the inhibitory effects of DHTMF, K562R
cells were treated with six concentrations of DHTMF for
24, 48, and 72 h, and cell viability was determined by the
CCK8 assay. When K562R cells were treated with DHTMF
for 24, 48, and 72 h, the inhibitory ratio increased withincreasing concentration (p < 0.05, p < 0.01). DHTMF at
concentrations of 24, 48, and 72 h exhibited inhibitory ef-
fects with IC50 concentrations of 7.85, 5.78, and 5.32 μg/mL,
respectively. When comparing with the same concentra-
tions at 24 h, the inhibitory ratio was also significantly
increased (p < 0.05, p < 0.01). As shown in Figure 2, these
results suggest that DHTMF suppresses cell viability in a
time- and dose-dependent manner.
To further observe the inhibitory effects of DHTMF
on K562R cells in the presence or absence of IM, K562R
cells were treated with different concentration combi-
nations (1 μmol/L IM, 2.5 μg/mL DHTMF, 5 μg/mL
DHTMF, 10 μg/mL DHTMF, 1 μmol/L IM +2.5 μg/mL
DHTMF, 1 μmol/L IM +5 μg/mL DHTMF, and 1 μmol/L
IM +10 μg/mL DHTMF) for 24, 48, and 72 h, and cell
viability was determined by the CCK8 assay. As shown in
Figure 3, inhibitory ratio was significantly increased by
DHTMF alone and in combination with IM (P < 0.01).
The inhibitory ratio was greater than 45% when 1 μmol/L
IM was combined with 5 μg/mL DHTMF for 24 h. Com-
pared with the same concentration of DHTMF at the
same time, the inhibitory activity was also increased
in K562R cells (P < 0.01). These results suggested that
DHTMF combined with IM enhances the inhibitory
effects of DHTMF on K562R cells.
DHTMF alone and in combination with imatinib induces
apoptosis in K562R cells
To investigate whether the inhibitory effects of DHTMF
in K562R cells is associated with apoptosis, treated K562R
cells were labeled with AV and PI and analyzed by flow
cytometry. Annexin V is an inner membrane protein with
a strong affinity for phosphatidylserine. Surface staining
of annexin V is used as a general indicator of apoptosis.
As shown in Figure 4, most K562R cells were viable in
Figure 2 The inhibitory effect of DHTMF in K562R cells at different treatment times. A: 24 h, B: 48 h, C: 72 h. **, P < 0.01 vs. 0.3125 μg/mL;
D: *, P < 0.05, **, P < 0.01 vs. the same concentration for 24 h.
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centration combinations (1 μmol/L IM, 5 μg/mL DHTMF,
and 1 μmol/L IM +5 μg/mL DHTMF) for 24 h. However,
after incubation with DHTMF alone or in combination
with IM for 24 h (Figure 5), the cells displayed an increaseFigure 3 The inhibitory effects of DHTMF, IM and the
combination of IM followed by DHTMF in K562R cells for 24,
48, and 72 h. A: 1 μmol/L IM; B: 2.5 μg/mL DHTMF; C: 5 μg/mL
DHTMF; D: 10 μg/mL DHTMF; E: 1 μmol/L IM +2.5 μg/mL DHTMF;
F: 1 μmol/L IM +5 μg/mL DHTMF; G: 1 μmol/L IM +10 μg/mL
DHTMF. **, P < 0.01 vs. 1 μmol/L IM at the same time, ##, P < 0.01 vs.
the same concentration as DHTMF alone at the same time.in the average apoptosis rate of the cells (Q4, AV positive
but PI negative) ranging from 4.5 ± 0.57% for the control
group and up to 5.4 ± 0.28%, 32.6 ± 0.14%, and 47.9 ±
0.01% for the treatment groups, respectively. K562R cells
treated with 5 μg/mL DHTMF or 1 μmol/L IM +5 μg/mL
DHTMF had a pronounced increase in apoptosis as indi-
cated by the increase in the AV+/PI − population (4.5% for
the control versus 32.6% for 5 μg/mL DHTMF, 5.4% for
1 μmol/L IM vs. 47.9% for 1 μmol/L IM +5 μg/mL
DHTMF, and 32.6% for 5 μg/mL DHTMF vs. 47.9% for
1 μmol/L IM +5 μg/mL DHTMF (P < 0.01, P < 0.01 and
P < 0.01, respectively).
DHTMF induces the apoptosis of K562R cells via the
mitochondrial apoptotic pathway
To understand the underlying mechanism by which
DHTMF alone and in combination with IM induces
apoptosis, we investigated changes in the mitochondrial
membrane potential and the level of proteins involved
in apoptosis.
First, we explored the effects of DHTMF on mitochon-
drial membrane potential. K562R cells were cultured in
different drug concentrations for 24 h and analyzed by
flow cytometry and laser confocal microscopy following
JC-1 staining (Figure 5A, B). Upon 5 μg/mL DHTMF or
1 μmol/L IM +5 μg/mL DHTMF treatment, the number
of cells displaying monomeric green fluorescence increased
compared with untreated cells and those exposed to
1 μmol/L IM. These data indicated that the mitochon-
drial membrane potential is significantly decreased by the
5 μg/mL DHTMF and 1 μmol/L IM +5 μg/mL DHTMF
Figure 4 Induction of apoptosis by DHTMF alone or combination of IM in K562R cells for 24 h treatment. A: Control; B: 1 μmol/L IM;
C: 5 μg/mL DHTMF; D: 1 μmol/L IM+5μg/mL DHTMF. P > 0.05, B vs. A; **, P < 0.01 vs. A; ##, P < 0.01 vs. B, ■■, P < 0.01 vs. C.
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This finding suggests that DHTMF alone and in com-
bination with IM disrupts the mitochondrial membrane
potential, resulting in the cytosolic accumulation of mo-
nomeric JC-1, which is an indicator of apoptosis via
activation of the intrinsic pathway.
Caspases are crucial players in the induction of apop-
totic cell death. Caspase-9 is an initiator caspase that has
been implicated in the mitochondria-dependent path-
way. To assess the effects of DHTMF alone and in com-
bination with IM on the cleavage of caspases and PARP,
cells were treated with different drug concentrations for
24 h, and total cell lysates were prepared for Western
blot analysis. As shown in Figure 6, DHTMF affected the
increase in the level of cleaved caspase-9, caspase-7,Figure 5 DHTMF alone or combination of IM induces mitochondria d
analyzed by flow cytometry.**, P < 0.01 vs. Control, ##, P < 0.01 vs. 1 μmol/L
dysfunction on K562R cells. Cells were analyzed with a laser confocal microcaspase-3, and PARP in K562R cells. In K562R cells trea-
ted with 5 μg/mL DHTMF and 1 μmol/L IM +5 μg/mL
DHTMF, the immunoreactivity of the cleaved caspases
and PARP were dramatically increased (P < 0.01, P < 0.01
and P < 0.01, respectively). These results indicate that
DHTMF alone and in combination with IM induces apop-
tosis in K562R cells via caspase-3, caspase-9, and caspase-7
activation, and DHTMF-induced apoptosis is associated
with the mitochondria-dependent pathway.
Discussion
Treatment with IM is the standard of care for patients
newly diagnosed with CML, while several second gener-
ation inhibitors, such as dasatinib and nilotinib, have
become available with the promise of overcoming someysfunction in K562R cells. A: Cells were stained with JC-1 dye and
IM, ■■, P < 0.01 vs. 5 μg/mL DHTMF. B: DHTMF induces mitochondria
scope, Bar = 20 μm.
Figure 6 Western blot analysis in K562R cells. The relative expression level of the cleaved proteins was analyzed for caspase-3 (A), caspase-9
(B), caspase-7 (C) and PARP (D). β-actin was used as a loading control. The results are presented as the ratio of cleaved proteins compared to
β-actin intensities. **, P < 0.01 vs. Control, ##, P < 0.01 vs. 1 μmol/L IM, ■■, P < 0.01 vs. 5 μg/mL DHTMF.
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these patients [18]. However, primary TKI therapy re-
sistance and relapse due to the persistence of leukemic
stem cells (LSCs) remain a major clinical problem. More-
over, TKI monotherapy is not curative. Recently, combin-
ation therapies such as the dual-targeting of the Bcr-Abl
and JAK2 activities have been shown to lead to more
effective disease eradication, particularly for CML patients
at high risk for TKI resistance and disease progression
[19,20]. Natural products, such as oridonin, which has
been shown to induce the apoptosis of t(8;21) acute mye-
loid leukemic (AML) cells and inhibit the activity of c-Kit
(+) leukemia-initiating cells [21,22], have been considered
to play an important role in treating cancer and drug re-
sistance, and they are promising and safe antitumor agents
due to their natural origin. DHTMF is a polymethoxy-
flavone isolated from Laggera pterodonta that is a trad-
itional herbal medicine. In a previous study, DHTMF
demonstrated antiproliferative activities against a number
of tumor cell lines and induced the apoptosis of CNE cellsin vitro in a time- and dose-dependent manner while exhi-
biting low cytotoxicity in the two normal cell lines Vero
and EVC304 [17]. Therefore, in this study, we used
DHTMF in IM-resistant K562 cells (K562R) to investigate
its anti-tumor effect. According to this finding, it would
be interesting to characterize the effects of DHTMF in
anti-leukemia therapy, particularly for the drug resistance
of refractory leukemia. In this study, we analyzed the
effects of DHTMF in IM-resistant K562 cells (K562R) and
found that DHTMF alone or in combination with IM
could significantly inhibit proliferation in a time- and
dose-dependent manner. As such, the inhibitory ratio was
36.36% when 5 μg/mL DHTMF was used alone for 24 h,
while 5 μg/mL DHTMF combined with 1 μg/mL IM could
increase the inhibitory activity to 46.63%. These results
suggest that DHTMF indeed has inhibitory effects in
K562R cells and at the same time improves the sensitivity
of K562R cells to IM. By flow cytometry, we confirmed
that the percentage of apoptotic cells was significantly
increased when K562R cells were treated with 5 μg/mL
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These findings indicate that DHTMF alone or in com-
bination with IM inhibits cell proliferation by inducing
apoptosis in K562R cells. There are two main apoptosis
pathways: the extrinsic death receptor pathway and the
intrinsic mitochondrial pathway [23]. Many polymethoxy-
flavone induce apoptosis via the mitochondrial apopto-
sis pathway [24-26]. To further investigate the potential
mechanisms of action involved using apoptosis-related
analysis, we first observed changes in the mitochondrial
membrane potential by flow cytometry and laser confocal
microscopy. The results showed that 5 μg/mL DHTMF
and 1 μmol/L IM +5 μg/mL DHTMF for 24 h significantly
decrease the mitochondrial membrane potential. These
results are consistent with the findings of previous studies
in which DHTMF was shown to induce the apoptosis of
CNE cells in vitro in a time- and dose-dependent manner
[17]. These changes suggest that DHTMF is likely to
induce apoptosis via the mitochondrial pathway. Caspases
are crucial players in the induction of apoptotic cell death.
Caspase-9 is an initiator caspase that has been impli-
cated in the mitochondria-dependent pathway [27]. In
this study, we demonstrated that DHTMF alone or in
combination with IM induces the cleavage of caspase-9,
caspase-3, caspase-7, and PARP in DHTMF-treated K562R
cells. DHTMF also markedly increased the levels of cleaved
caspases and PARP, indicating that the apoptosis me-
chanism in DHTMF-treated K562R cells might be medi-
ated by activation of the mitochondrial apoptotic pathway
and subsequently activate the caspase pathway. Further
study is required to elucidate additional mechanisms
underlying DHTMF function and determine the exact
molecular mechanisms of action of DHTMF in CML
cells with IM resistance.
Conclusions
We demonstrated for the first time that DHTMF alone
or in combination with IM inhibits IM-resistant K562R
cell proliferation and induces apoptosis via the intrinsic
mitochondrial apoptotic pathway. Moreover, DHTMF can
improve the sensitivity of K562R to IM. These findings
suggest that DHTMF may be a potential therapeutic drug
with few side effects in reversing IM-resistance in CML.
Whether DHTMF has other effects on Abl-mutated CML
cells is worth investigating.
Methods
Polymethoxyflavone, cell, and reagents
3,5-Dihydroxy-6,7,3′,4′-tetramethoxyflavone (DHTMF)
was isolated from Laggera pterodonta, and its struc-
ture was identified with spectroscopic methods [28]. IM-
sensitive K562 cells (Institutes for Biological Sciences Cell
Resource Center, Chinese Academy of Sciences, Shanghai,
China) harboring 210 kDa wild-type Bcr-Abl were grownin RPMI 1640 medium (Gibco-BRL, Grand Island, NY,
USA) supplemented with 10% fetal calf serum (FCS)
(Sijiqing Co., Hangzhou, China) and maintained in a
humidified incubator at 37°C and 5% CO2. IM-resistant
K562R cells (provided by Prof. Jingxuan Pan, Sun Yat-sen
University, Guangzhou, China) harboring 210 kDa wild-
type Bcr-Abl were routinely maintained in the same
medium containing 5 μmol/L IM [29]. Three days
before the experiments were performed, IM was no
longer added to the media for cell culture.
Cell proliferation assays
The proliferation of K562R and K562 cells was indirectly
assayed using the CCK8 kit (Dojindo, Japan), which stains
living cells. Approximately 1 × 105 K562R and K562 cells
in 1 mL with 0.1, 1, 10, 100, 1,000 μmol/L IM or different
concentrations of DHTMF alone or in combination with
IM were incubated in triplicate in 96-well plates. At 24,
48, and 72 h, the CCK8 reagent (10 μL) was added to each
well, and the cells were incubated at 37°C for 6 h. The
optical density at 450 nm was measured using an auto-
matic microplate reader (Synergy4; Bio-Tek, Winooski,
VT, USA). IC50 values were determined by plotting com-
pound concentration versus cell viability.
Apoptosis analysis
At 24 h, K562R cells were treated with or without
1 μmol/L IM, 5 μg/mL DHTMF, or 1 μmol/L IM +5 μg/mL
DHTMF. The cells were collected and then prepared with
FITC-labeled anti-annexin-V (anti-AV, BD Pharmingen,
San Diego, CA, USA) and propidium iodide (PI, Kaiji,
Nanjing, China) according to the manufacturer’s proto-
col and measured by flow cytometry (Beckman Coulter,
Fullerton, CA, USA). The data were analyzed using
Windows MDI 2.9 software.
Detection of mitochondrial transmembrane potential
using flow cytometry and confocal laser-scanning
microscopy
Changes in mitochondrial potential were detected by using
5,5′,6,6′-tetrachloro-1,1′,3,3′ tetraethyl benzimidazolyl car-
bocyanine iodide/chloride (JC-1), a cationic dye that ex-
hibits potential-dependent accumulation in mitochondria.
These changes were indicated by a fluorescence emission
shift from red (590 nm) to green (525 nm), and they were
analyzed by flow cytometry. At 24 h, K562R cells were
treated with or without 1 μmol/L IM, 5 μg/mL DHTMF,
and 1 μmol/L IM +5 μg/mL DHTMF. The cells were col-
lected, washed with phosphate-buffered saline (PBS), and
analyzed on a flow cytometer. The %Parent green fluores-
cence cells was calculated for each treatment. At 24 h,
K562R cells were treated with or without 1 μmol/L IM,
5 μg/mL DHTMF, and 1 μmol/L IM +5 μg/mL DHTMF.
The cells were collected, washed twice with PBS, and
Cao et al. Cancer Cell International 2014, 14:137 Page 7 of 8
http://www.cancerci.com/content/14/1/137stained with JC-1 dye staining. Changes in the mito-
chondrial transmembrane potential of the cells after JC-1
dye staining were observed with a confocal laser-scanning
microscope (LSM 510 META DuoScan; Carl Zeiss,
Germany).
Preparation and analysis of cell lysates by
immunoblotting
At 24 h, K562R cells were treated with or without
1 μmol/L IM or 5 μg/mL DHTMF or their combination
and were harvested and western blotting was carried out
Protein quantification was performed according to con-
ventional methods. Protein samples (30 μg) were boiled
with 5 × loading buffer at 100°C for 5 min before being
loaded, and they were then electrophoresed in a 12%
SDS-PAGE gel at 80 V for 30 min followed by 120 V for
60 min (Bio-Rad). The separated proteins were transferred
onto equilibrated PVDF membranes (Invitrogen) using a
tank system (Bio-Rad). After blocking with 5% skim milk
in TBST for 1 h, the membrane was incubated with
individual primary antibodies including β-catenin (mouse
anti-actin antibody, 1:1,000 dilution, Lianke, Hangzhou,
China), cleaved caspase-3, cleaved caspase-9, cleaved
caspase-7 and cleaved PARP (1:1,000 dilution, Cell
signaling, Cleaved Caspase Antibody Sampler Kit Cat. No.
#9929) at 4°C overnight followed by incubation with goat
anti-rabbit or donkey anti-mouse IgG antibodies (Cell sig-
naling, Cleaved Caspase Antibody Sampler Kit Cat. No. #
9929; Lianke, Hangzhou, China). Immunoreactive proteins
were visualized by chemiluminescence (Lianke, Hangzhou,
China), and images were obtained with a Vilber Lourmat
system (UVI, UK). The protein expression level was cal-
culated with image quantitative analysis software using
β-actin as a reference gene.
Statistical analysis
Statistical significance was evaluated by one-way ANOVA
using SPSS 11.5 statistical software. The results were
considered significant at p value less than 0.05.
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